Association between uveitis onset and economic development in mainland China.
Disease burden
Gross domestic product
Uveitis
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
04 09 2023
04 09 2023
Historique:
received:
11
03
2023
accepted:
23
08
2023
medline:
6
9
2023
pubmed:
5
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Economic prosperity has fostered numerous changes that may translate into better or worse outcomes across all domains of health. This study aims to explore the associations of economic development with uveitis onset in mainland China. We used Poisson regression with generalized estimated equations to quantify the associations of per capita gross domestic product (GDP) with uveitis onset in 31 provinces of mainland China from 2006 to 2017. We further estimated the effects mediated by economic growth on the temperature-uveitis and PM2.5-uveitis associations established in our previous studies. A total of 12,721 uveitis patients from 31 provinces of mainland China were studied. Overall, every 10,000 Chinese yuan ($ 1491.278, 2006-2017) increase in per capita GDP, with no weighted value or weighted by population, corresponded to 1.85% (95% confidence interval, 1.19-2.52%) and 1.43% (95% confidence interval, 0.37-2.51%) lnRR decrease in the uveitis onsets. Stratified analysis showed this negative association between per capita GDP and uveitis onset, only existed in male patients (P < .001), individuals aged 20-50 years (P < 0 .05), non-infectious uveitis, uveitis with systemic disease, and Bechet's disease (all P < 0 .05). Moreover, the increased per capita GDP, if above the national level, could reinforce both temperature-uveitis and PM2.5-uveitis association (both P < 0.001). The findings suggest that economic development is negatively associated with uveitis onset. However, it may facilitate the uveitis onset mediated by both increased temperature and PM2.5 exposure if the per capita GDP is above national level.
Sections du résumé
BACKGROUND
Economic prosperity has fostered numerous changes that may translate into better or worse outcomes across all domains of health. This study aims to explore the associations of economic development with uveitis onset in mainland China.
METHODS
We used Poisson regression with generalized estimated equations to quantify the associations of per capita gross domestic product (GDP) with uveitis onset in 31 provinces of mainland China from 2006 to 2017. We further estimated the effects mediated by economic growth on the temperature-uveitis and PM2.5-uveitis associations established in our previous studies.
RESULTS
A total of 12,721 uveitis patients from 31 provinces of mainland China were studied. Overall, every 10,000 Chinese yuan ($ 1491.278, 2006-2017) increase in per capita GDP, with no weighted value or weighted by population, corresponded to 1.85% (95% confidence interval, 1.19-2.52%) and 1.43% (95% confidence interval, 0.37-2.51%) lnRR decrease in the uveitis onsets. Stratified analysis showed this negative association between per capita GDP and uveitis onset, only existed in male patients (P < .001), individuals aged 20-50 years (P < 0 .05), non-infectious uveitis, uveitis with systemic disease, and Bechet's disease (all P < 0 .05). Moreover, the increased per capita GDP, if above the national level, could reinforce both temperature-uveitis and PM2.5-uveitis association (both P < 0.001).
CONCLUSIONS
The findings suggest that economic development is negatively associated with uveitis onset. However, it may facilitate the uveitis onset mediated by both increased temperature and PM2.5 exposure if the per capita GDP is above national level.
Identifiants
pubmed: 37667273
doi: 10.1186/s12889-023-16591-x
pii: 10.1186/s12889-023-16591-x
pmc: PMC10476315
doi:
Substances chimiques
Particulate Matter
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1711Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Rev Psiquiatr Salud Ment (Engl Ed). 2018 Apr - Jun;11(2):115-124
pubmed: 28993125
Curr Mol Med. 2018 Mar 9;17(7):468-470
pubmed: 29424311
Expert Rev Clin Immunol. 2014 Aug;10(8):981-3
pubmed: 24961712
Int J Obes (Lond). 2017 Feb;41(2):352
pubmed: 27885270
N Engl J Med. 2008 Jun 5;358(23):2468-81
pubmed: 18525043
Ann Intern Med. 1998 Sep 1;129(5):406-11
pubmed: 9735069
Ocul Immunol Inflamm. 2023 Jul;31(5):1041-1060
pubmed: 35759636
Ocul Immunol Inflamm. 2023 Feb;31(2):367-373
pubmed: 35201961
Br J Ophthalmol. 2022 Jan;106(1):91-96
pubmed: 33055083
J Clin Invest. 2019 Sep 3;129(9):3482-3491
pubmed: 31478909
Ocul Immunol Inflamm. 2022 Oct-Nov;30(7-8):1810-1815
pubmed: 34379033
PLoS One. 2012;7(11):e47533
pubmed: 23185241
Sci Rep. 2021 Jan 26;11(1):2250
pubmed: 33500465
Nat Rev Dis Primers. 2021 Sep 16;7(1):67
pubmed: 34531393
Surv Ophthalmol. 2016 Jan-Feb;61(1):1-17
pubmed: 26164736
Arthritis Res Ther. 2016 Oct 3;18(1):217
pubmed: 27716399
JAMA Pediatr. 2019 Jul 1;173(7):e190914
pubmed: 31058915
Ocul Immunol Inflamm. 2018;26(1):2-16
pubmed: 27467180
CNS Neurol Disord Drug Targets. 2016;15(4):477-88
pubmed: 26996173
Ann Rheum Dis. 2009 Nov;68(11):1666-72
pubmed: 19643759
Front Immunol. 2022 Jan 31;13:830497
pubmed: 35173740
Br J Ophthalmol. 2018 Feb;102(2):215-219
pubmed: 28607176
Infect Dis Poverty. 2020 Jan 28;9(1):10
pubmed: 31987053
Nat Rev Rheumatol. 2016 Oct;12(10):605-20
pubmed: 27558659
Health Psychol. 2000 Nov;19(6):586-92
pubmed: 11129362
Thorax. 2022 Nov;77(11):1057-1058
pubmed: 34853155
Prog Retin Eye Res. 2011 Nov;30(6):452-70
pubmed: 21807112
Ann Rheum Dis. 2016 May;75(5):942-3
pubmed: 26888946
Clin Exp Immunol. 2019 Jan;195(1):10-14
pubmed: 30569518
Front Immunol. 2022 Jun 24;13:878471
pubmed: 35812462
Ocul Immunol Inflamm. 2022 Feb 17;30(2):324-329
pubmed: 33026932
Autoimmun Rev. 2014 Jun;13(6):641-54
pubmed: 24418307
Br J Ophthalmol. 2020 Oct;104(10):1467-1471
pubmed: 31272954
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1037-1039
pubmed: 35040720
BMJ. 2018 Oct 31;363:k4306
pubmed: 30381293
Diabetologia. 2008 Nov;51(11):1980-8
pubmed: 18777168
Lancet. 2023 Jun 3;401(10391):1878-1890
pubmed: 37156255
JAMA. 2014 May 14;311(18):1912-3
pubmed: 24825646
J Rheumatol. 1988 Oct;15(10):1457-60
pubmed: 3204595
Br J Ophthalmol. 2021 Jan;105(1):75-82
pubmed: 32188681